Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Huddinge – page 6

218 clinical trials in Huddinge, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Huddinge at a glance
218
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

218 trials in Huddinge

Open in trial search

Pancreatic carcinoma

Recruiting

Study on the Effectiveness of Oxaliplatin or Gemcitabine Chemotherapy in Patients with Resected Pancreatic Cancer Using Standard or Genetic Allocation Methods

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Pancreatic carcinoma

Recruiting

A Study of FOLFIRINOX Drug Combination Before Surgery Compared to Immediate Surgery in Patients with Resectable Pancreatic Head Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Oslo University Hospital HF

Rheumatoid arthritis

Recruiting

Study Comparing Conventional Therapy and Biologic Treatments for Early Rheumatoid Arthritis Using Hydroxychloroquine, Abatacept, and Azathioprine in Responsive Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Karolinska Institutet

Pneumonia

Recruiting

Study on the Effects of Oseltamivir and Drug Combination for Patients with Pneumonia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Baloxavir Marboxil
  • Sponsor:University Of Oxford

B-cell lymphoma+2

Recruiting

Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tisagenlecleucel
  • Sponsor:Novartis Pharma Services AG

Staphylococcal bacteraemia

Recruiting

Study Comparing Benzylpenicillin and Cloxacillin for Treating Staphylococcus Aureus Blood Infection in Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cloxacillin
  • Sponsor:Region Skane

Myelodysplastic syndrome

Recruiting

Study on Azacitidine for Patients with Myelodysplastic Syndrome After Stem Cell Transplantation

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Karolinska University Hospital

Chronic kidney disease+1

Recruiting

Study on the Long-Term Safety of Finerenone with ACE Inhibitors or ARBs for Children and Young Adults with Chronic Kidney Disease and Proteinuria

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Alpha-1 antitrypsin deficiency

Recruiting

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency Liver Disease and Mild Fibrosis

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

IgA nephropathy

Recruiting

Long-Term Safety Study of Iptacopan for Adults with IgA Nephropathy After Completing a Previous Study, Including ACE Inhibitors and ARBs Drug Combination

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Plasma cell myeloma refractory

Recruiting

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.

Type 2 diabetes mellitus+1

Recruiting

Study on the Effects of Empagliflozin, Pioglitazone, and Semaglutide for Patients with Type 2 Diabetes

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Karolinska University Hospital

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Huddinge

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies exploring treatments for heart failure prevention and cardiovascular disease, including investigations into cholesterol metabolism and blood pressure management.

  • PCSK9 inhibitors and statins research
  • Heart failure prevention trials
  • Lipoprotein management studies

Comprehensive research focusing on reducing cardiovascular events and improving patient outcomes.

02 Oncology Studies

Groundbreaking research in blood cancers, including acute myeloid leukemia and multiple myeloma, with innovative therapeutic approaches.

  • Advanced breast cancer treatments
  • Leukemia therapy combinations
  • CAR T Cell therapy trials

Studies evaluating novel treatment combinations and targeted therapies for various cancer types.

03 Neurological Disorders

Clinical investigations focusing on Alzheimer's disease and amyotrophic lateral sclerosis, exploring innovative therapeutic approaches.

  • Cognitive impairment treatments
  • ALS survival studies
  • Inflammatory response research

Studies examining new therapeutic options for progressive neurological conditions.

04 Chronic Conditions

Research initiatives addressing chronic kidney disease, cystic fibrosis, and other long-term health conditions.

  • Kidney disease management
  • Diabetes treatment studies
  • Organ transplant research

Comprehensive studies aimed at improving quality of life for patients with chronic conditions.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.